TY - JOUR
T1 - Synthesis, radiolabeling and preclinical evaluation of a [11C]GMOM derivative as PET radiotracer for the ion channel of the N-methyl-D-aspartate receptor
AU - Klein, Pieter J.
AU - Schuit, Robert C.
AU - Metaxas, Athanasios
AU - Christiaans, Johannes AM
AU - Kooijman, Esther
AU - Lammertsma, Adriaan A.
AU - van Berckel, Bart NM
AU - Windhorst, Albert D.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Introduction Presently available PET ligands for the NMDAr ion channel generally suffer from fast metabolism. The purpose of this study was to develop a metabolically more stable ligand for the NMDAr ion channel, taking [11C]GMOM ([11C]1) as the lead compound. Methods [11C]1, its fluoralkyl analogue [18F]PK209 ([18F]2) and the newly synthesized fluorovinyloxy analogue [11C]7b were evaluated ex vivo in male Wistar rats for metabolic stability. In addition, [11C]7b was subjected to a biodistribution study and its affinity (Ki) and lipophilicity (logD7.4) values were determined. Results The addition of a vinyl chain in the fluoromethoxy moiety did not negatively alter the affinity of [11C]7b for the NMDAr, while lipophilicity was increased. Biodistribution studies showed higher uptake of [11C]7b in forebrain regions compared with cerebellum. Pre-treatment with MK-801 decreased the overall brain uptake significantly, but not in a region-specific manner. 45 min after injection 78, 90 and 87% of activity in the brain was due to parent compound for [11C]1, [18F]2 and [11C]7b, respectively. In plasma, 26–31% of activity was due to parent compound. Conclusion Complete substitution of the alpha-carbon increased lipophilicity to more favorable values. Substitution of one or more hydrogens of the alpha-carbon atom in the methoxy moiety improved metabolic stability. In plasma, more parent compound was found for [18F]2 and [11C]7b then for [11C]1, although differences were not significant. At 45 min, significantly more parent [18F]2 and [11C]7b was measured in the brain compared with [11C]1.
AB - Introduction Presently available PET ligands for the NMDAr ion channel generally suffer from fast metabolism. The purpose of this study was to develop a metabolically more stable ligand for the NMDAr ion channel, taking [11C]GMOM ([11C]1) as the lead compound. Methods [11C]1, its fluoralkyl analogue [18F]PK209 ([18F]2) and the newly synthesized fluorovinyloxy analogue [11C]7b were evaluated ex vivo in male Wistar rats for metabolic stability. In addition, [11C]7b was subjected to a biodistribution study and its affinity (Ki) and lipophilicity (logD7.4) values were determined. Results The addition of a vinyl chain in the fluoromethoxy moiety did not negatively alter the affinity of [11C]7b for the NMDAr, while lipophilicity was increased. Biodistribution studies showed higher uptake of [11C]7b in forebrain regions compared with cerebellum. Pre-treatment with MK-801 decreased the overall brain uptake significantly, but not in a region-specific manner. 45 min after injection 78, 90 and 87% of activity in the brain was due to parent compound for [11C]1, [18F]2 and [11C]7b, respectively. In plasma, 26–31% of activity was due to parent compound. Conclusion Complete substitution of the alpha-carbon increased lipophilicity to more favorable values. Substitution of one or more hydrogens of the alpha-carbon atom in the methoxy moiety improved metabolic stability. In plasma, more parent compound was found for [18F]2 and [11C]7b then for [11C]1, although differences were not significant. At 45 min, significantly more parent [18F]2 and [11C]7b was measured in the brain compared with [11C]1.
KW - GMOM
KW - Ion channel
KW - NMDA
KW - PET
KW - Uncompetitive antagonists
KW - [F]PK-209
UR - http://www.scopus.com/inward/record.url?scp=85019414407&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.nucmedbio.2017.05.003
DO - https://doi.org/10.1016/j.nucmedbio.2017.05.003
M3 - Article
SN - 0969-8051
VL - 51
SP - 25
EP - 32
JO - Nuclear Medicine and Biology
JF - Nuclear Medicine and Biology
ER -